Armed ATC not only may function as Her2 specific cytotoxic T lymphocytes in prostate cancer patients, but also may divide and secrete Th1 cytokines and RANTES and MIP1-α after binding to Her2+ tumors leading to recruitment of endogenous T cells and monocytes leading to in situ vaccination at the tumor site [30]. The gene discussed is CCL3; the disease is neoplasm.